Procept Bio Robotics Corp PRCT
We take great care to ensure that the data presented and summarized in this overview for PROCEPT BioRobotics Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRCT
View all-
Vanguard Group Inc Valley Forge, PA5.25MShares$203 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$135 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.16MShares$83.3 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.53MShares$59 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.32MShares$51 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.3MShares$50.1 Million0.01% of portfolio
-
State Street Corp Boston, MA1.27MShares$49 Million0.0% of portfolio
-
Loomis Sayles & CO L P1.17MShares$45.2 Million0.09% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.07MShares$41.3 Million0.46% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI939KShares$36.3 Million0.09% of portfolio
Latest Institutional Activity in PRCT
Top Purchases
Top Sells
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Insider Transactions at PRCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 14
2025
|
Antal Rohit Desai Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,749
+43.21%
|
$26,749
$1.33 P/Share
|
|
Aug 14
2025
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+13.18%
|
$44,000
$4.52 P/Share
|
|
Aug 13
2025
|
Frederic H Moll Director |
BUY
Open market or private purchase
|
Direct |
20,000
+2.26%
|
$780,000
$39.26 P/Share
|
|
Jun 12
2025
|
Antal Rohit Desai Director |
SELL
Open market or private sale
|
Indirect |
25,000
-38.35%
|
$1,525,000
$61.81 P/Share
|
|
Jun 11
2025
|
Antal Rohit Desai Director |
SELL
Open market or private sale
|
Indirect |
25,000
-15.03%
|
$1,575,000
$63.44 P/Share
|
|
Jun 10
2025
|
Antal Rohit Desai Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+15.47%
|
-
|
|
Jun 10
2025
|
Antal Rohit Desai Director |
SELL
Open market or private sale
|
Indirect |
25,000
-9.95%
|
$1,575,000
$63.97 P/Share
|
|
Jun 10
2025
|
Taylor C. Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+1.53%
|
-
|
|
Jun 10
2025
|
Larry L Wood Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+20.49%
|
-
|
|
Jun 10
2025
|
Elisabeth Sandoval Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+10.91%
|
-
|
|
Jun 10
2025
|
Frederic H Moll Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+0.18%
|
-
|
|
Jun 10
2025
|
Amy M. Dodrill Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+16.78%
|
-
|
|
Jun 10
2025
|
Mary Garrett Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+9.66%
|
-
|
|
Jun 10
2025
|
Thomas M Prescott Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,538
+28.3%
|
-
|
|
Jun 06
2025
|
Hisham Shiblaq EVP, Chief Comm. Officer |
SELL
Open market or private sale
|
Direct |
20,000
-8.63%
|
$1,280,000
$64.57 P/Share
|
|
Jun 06
2025
|
Hisham Shiblaq EVP, Chief Comm. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+19.39%
|
$100,000
$5.18 P/Share
|
|
Jun 05
2025
|
Antal Rohit Desai Director |
SELL
Open market or private sale
|
Indirect |
25,000
-3.94%
|
$1,600,000
$64.48 P/Share
|
|
Jun 04
2025
|
Antal Rohit Desai Director |
SELL
Open market or private sale
|
Indirect |
25,000
-9.38%
|
$1,525,000
$61.11 P/Share
|
|
Jun 03
2025
|
Antal Rohit Desai Director |
SELL
Open market or private sale
|
Indirect |
25,000
-3.2%
|
$1,500,000
$60.09 P/Share
|
|
May 09
2025
|
Reza Zadno President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,759
+6.86%
|
$96,313
$7.27 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 94.4K shares |
|---|---|
| Exercise of conversion of derivative security | 470K shares |
| Open market or private purchase | 20K shares |
| Other acquisition or disposition | 895K shares |
|---|---|
| Open market or private sale | 998K shares |